Particle.news
Download on the App Store
3 ARTICLES
·
3d ago

Mayo Clinic Administers First U.S. Alpha-Emitter Therapy for Metastatic Breast Cancer

Enrollment for the TRACY-1 trial is underway at Mayo Clinic’s three campuses alongside roughly 20 other U.S. sites following the initial actinium-225 dose.

Mayo Clinic Treats First Person in the US With a Novel Radiopharmaceutical Therapy for Breast Cancer

Overview

  • The first dose of actinium-225-labeled DOTATATE was given to an ER+, HER2-negative metastatic breast cancer patient at Mayo Clinic Florida under the TRACY-1 phase 1b/2 trial
  • Actinium-225 emits alpha particles that are about 8,000 times more massive than beta particles and travel only three cell diameters, focusing potent radiation on tumor cells
  • The open-label study spans Mayo Clinic sites in Rochester, Phoenix and Jacksonville as well as approximately 20 additional centers across the U.S.
  • The investigational agent 225Ac-DOTATATE (RYZ101) was developed and sponsored by RayzeBio Inc., building on preclinical data showing feasibility against somatostatin receptor–positive breast tumors
  • Mayo Clinic currently conducts nearly 20 active radiopharmaceutical therapy trials and is preparing 10 more to expand targeted radioactive medicine